By Stephen Nakrosis
Portage Biotech have more than doubled in the after-hours market after the company reported preclinical results for PORT-7 in a murine mesothelioma model.
In the Thursday late trading session, the company's shares were at $10.62, with volume topping 1.2 million shares. The stock gained 3.7% in the day's regular session, closing at $4.71.
Portage said the data showed both single agent activity for PORT-7, and a dramatic inhibition of tumor growth when PORT-7 was combined with an anti-PD1 antibody in a murine model of mesothelioma.
The company said, to their knowledge, their's was the first report of antitumor activity against mesothelioma using a selective A2B receptor inhibitor. Portage added it is making preparations to commence a first-in-human clinical trial with PORT-7.
Portage also said it is advancing the dose escalation of PORT-6, an A2A adenosine receptor.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
March 27, 2025 18:02 ET (22:02 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。